Patritumab deruxtecan in HER-3 expressing metastatic breast cancer
A phase I/II trial shows that this HER3-targeted antibody-drug conjugate has a manageable safety profile and durable efficacy in heavily pretreated patients across clinical subtypes
Day: December 18, 2023